Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non–Small Cell Lung Cancer and Bone Metastases: A Systematic Review-Reference-Cited by-同舟云学术

Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non–Small Cell Lung Cancer and Bone Metastases: A Systematic Review

Published:2016-02 Issue:2 Volume:11 Page:155-173
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hendriks Lizza E.L.,Hermans Bregtje C.M.,van den Beuken—van Everdingen Marieke H.J.,Hochstenbag Monique M.H.,Dingemans Anne-Marie C.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference52 articles.

1. Metastatic bone disease: clinical features, pathophysiology and treatment strategies;Coleman;Cancer Treat Rev,2001

2. Incidence and distribution of skeletal metastases in NSCLC in the era of PET;Kosteva;Lung cancer,2004

3. Skeletal metastases in non–small cell lung cancer: a retrospective study;Tsuya;Lung cancer,2007

4. Metastatic non–small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

5. Bone health in cancer patients: ESMO Clinical Practice Guidelines;Coleman;Ann Oncol,2014

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone targeted nano-drug and nano-delivery;Bone Research;2024-09-04

2. Bibliometric analysis of bone metastases from lung cancer research from 2004 to 2023;Frontiers in Oncology;2024-08-06

3. Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors;Frontiers in Immunology;2024-04-18

4. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors;Lung Cancer;2023-12

5. Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib;JTO Clinical and Research Reports;2023-05